tbuckley/cabot-search huggingface dataset:
National Cancer Genetics Network
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: Yasuji Arase
Journal: Hepatology (2009)

We are pleased with the interest in our article1 and appreciate the useful comments made by Dr. Tugrul Purnak. He eloquently discussed the onset of diabetes mellitus. We agree with Dr. Tugrul Purnak. The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors of type 2 diabetes after the termination of interferon therapy in hepatitis C virus–positive patients. In the present study, we wanted to determine whether the clearance of hepatitis C virus reduces the risk of type 2 diabetes development. Unfortunately, in this study, we could not evaluate the smoking status, family history of diabetes, hypertension, apolipoprotein, or genetic factors. With respect to changes in the body mass index (BMI), some patients experiencing the onset of diabetes were measured during follow-up, as shown in Table 1. In patients without a sustained virological response, the BMI was almost the same. On the other hand, in patients with a sustained virological response, the mean BMI increased by about 1.0.This means that in patients without a sustained virological response, the onset of diabetes is enhanced without an increase in the BMI. Yasuji Arase M.D.*, * Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
A7.1 A Genetic Variant in the Region of<i>MMP-9</i>is Associated with Serum Levels and Progression of Joint Damage in Rheumatoid Arthritis
Authors: DPC de Rooy, A Zhernakova, R Tsonaka, A Willemze, BAS Kurreeman, REM Toes, TWJ Huizinga, JJ Houwing-Duistermaat, PK Gregersen, AHM van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background and Objectives</h3> The severity of joint destruction is highly variable between Rheumatoid Arthritis (RA) patients. We aimed to identify new genetic risk factors by studying genetic susceptibility loci of several auto-immune diseases. <h3>Patients and Methods</h3> In phase-1, 646 Dutch RA-patients with yearly X-rays of hands and feet over 7 years follow-up were genotyped for 148,880 SNPs by Immunochip which contains 186 loci previously associated with autoimmune diseases. Association of SNPs with MAF &gt; 0.01 (130,841 SNPS) with joint destruction was analysed using a marginal regression model. Correction for multiple testing was done by Bonferroni correction for the number of uncorrelated SNPs (threshold p &lt; 1.1 × 10<sup>–6</sup>). In phase-2, 686 North American RA-patients with repeated hands X-rays over 15 years follow-up, for which Immunochip genotyping data were also available, were studied. SNPs that were significantly associated in phase-1 were selected and evaluated. All X-rays were scored by Sharp van der Heijde score (ICC 0.91 and 0.98 for phase-1 and 2 respectively). MMP-9 levels were measured in baseline serum by ELISA (Ebioscience) in 120 RA-patients that were selected on the Rs11908352-genotype. <h3>Results</h3> In phase-1, 109 SNPs were significantly associated with joint destruction (p &lt; 1.1 × 10<sup>–6</sup>). Of these, 76 variants were on the HLA region. The 33 non-HLA genetic variants, though several were in high LD, were studied in the North-American RA-patients. Here, after correction for the number of uncorrelated SNPs (threshold p &lt; 0.0036), two variants were associated with the severity of joint destruction: Rs451066 on chromosome 14 (p<sub>uncorrected</sub> = 0.002, MAF = 0.20) and Rs11908352 on chromosome 20 (p<sub>uncorrected</sub> = 0.002, MAF = 0.21). The region of Rs451066 on chromosome 14 has previously been linked to type-1 diabetes susceptibility. Presence of a risk allele was associated with a 3.7% higher rate of joint destruction per year; this equaled 29% over 7-years. Rs11908352 is located at the <i>MMP-9</i> region on chromosome 20. Patients with a risk allele had a 2.7% higher radiological progression rate per year, which equaled 20% more joint destruction over a 7-years period. Furthermore, the minor genotype was associated with significantly higher levels of MMP-9 compared to the common genotype (p = 0.007). <h3>Conclusions</h3> Two new risk loci for progressive joint destruction in RA were identified (Rs451066 and Rs1190852). The risk allele in Rs11908352 also associated with higher serum MMP-9 levels, indicating to a role for MMP-9 in progression of joint destruction in RA. <h3>Acknowledgements</h3> RACI study group, Dutch Arthritis Foundation, Netherlands organisation for scientific research.
Minerva
Journal: BMJ (2005)

A paper entitled Cooking up Fine Remedies in Medical History (2005;49:395-422) includes the following recipe for treating white tiger wind sickness.Use three skewers of pork.Combine with hempseed and half a cup of wine, and hold in the mouth so as to apply by spraying from the lips.Apply the meat to the affected part, chanting.So much more poetic and magical than simply writing, "Apply to affected area."
Biogeochemical Processes Governing Exposure and Uptake of Organic Pollutant Compounds in Aquatic Organisms
Authors: John W. Farrington
Journal: Environmental Health Perspectives (1991)

This paper reviews current knowledge of biogeochemical cycles of pollutant organic chemicals in aquatic ecosystems with a focus on coastal ecosystems.There is a bias toward discussng chemkal and geochemical aspects ofbiogeochemical cycles and an emphasis on hydrophobic organic compounds such as polynuckar aromatic hydrocarbons, polychlorinated biphenyls, and chlorinated organic compounds used as pesticides.The complexity of mixtures of pollutant organic com- pounds, their various modes ofentering ecosystems, and their physical chemical forms are discussed.Important factors that influence bioavailability and disposition (e.g., organism-water partitioning, uptake via food, food meb transfer) are reviewed.These factors include solubilities ofchemicals; partitioning ofchemicals between solid surfaces, colloids, and soluble phases; variables rates of sorption, desorption; and physiological status of organism.It appears that more em- phasis on considering food as a source of uptake and bioaccumulation is important in benthic and epibenthic ecosystems when sediment-associated pollutants are a nt source ofinput to an aquatic ecosystem.Progress with mathematical models for exposure and uptake of contaminant chemicals is discussed briefly.
Treatment of the Hypereosinophilic Syndrome with Interferon-α
Authors: Joseph H. Butterfield
Journal: Annals of Internal Medicine (1995)

Letters15 July 1995Treatment of the Hypereosinophilic Syndrome with Interferon-αJoseph H. Butterfield, MD and Gerald J. Gleich, MDJoseph H. Butterfield, MDSearch for more papers by this author and Gerald J. Gleich, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-2-199507150-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We read with interest the letter by Papo and colleagues. Although it is difficult to make a generalization on the basis of a brief case report, we hesitate to call their experience a clinical failure because of the apparent low dose of interferon-α used (5 MU three times a week). In our experience, the dose of interferon-α necessary for initial control of the hypereosinophilic syndrome has been as high as 8 MU/d. This dose can often subsequently be decreased. Among many patients in our study, we noted a wide dose range that was initially necessary for control of ... Author, Article, and Disclosure InformationAuthors: Joseph H. Butterfield, MD; Gerald J. Gleich, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 July 1995Volume 123, Issue 2Page: 156KeywordsEosinophilia ePublished: 15 August 2000 Issue Published: 15 July 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Expanded access program (EAP) to investigational drugs
Authors: L. Talarico, R. Pazdur
Journal: Journal of Clinical Oncology (2004)

6001 Background: Title 21 part 312.34 of the Code of Federal Regulations provides for use of unapproved drugs to treat patients with serious or immediately life-threatening diseases ineligible for clinical trials and without available alternative therapy. EAPs can provide drugs to individual patients under “single patient Investigational New Drug (IND)” and to larger numbers under “treatment IND”. EAPs are implemented while sponsors are actively pursuing marketing approval. Reasonable evidence of clinical usefulness for the indication and sufficient safety information from ongoing or completed trials are required. EAPs are voluntarily initiated by the drug sponsor. FDA and IRB approvals and safety monitoring are required. Methods: Review of data reported from EAPs for the following drugs (indications): imatinib (chronic myelogenous leukemia), trastuzumab (breast cancer), temozolomide (malignant gliomas), oxaliplatin (colorectal cancer), gemcitabine (pancreatic cancer), gefitinib (non-small cell lung cancer). Results: The number of patients in each EAP ranged from 168 to 24,261, total 42,828, median 5182 (169, 11965). No new safety concerns were raised in the EAPs. For example, the incidence of interstitial lung disease in patients receiving gefitinib was about 2% in the Japanese post-marketing experience and 0.3% in about 24.000 patients in the U.S. EAP. Efficacy outcomes were consistent with registration trials. Selected EAPs provided additional information, such as tolerability of gefitinib in elderly, identification of factors predictive of response to oxaliplatin-based treatment. Conclusions: Disseminated information on new drugs in clinical development encourages patients without available treatments to seek new therapeutic options. Patients with common tumors comprise large EAP populations. EAPs are effective mechanisms to provide investigational drugs to patients and obtain additional safety information from larger, more heterogeneous populations. While providing investigational drugs to all patients who may benefit, EAPs could be designed to provide additional clinical information such as subpopulation analyses of outcome, dose ranging, drug combinations. No significant financial relationships to disclose.
Immune System Research Underlies Lasker Awards
Journal: Cancer Discovery (2019)

Abstract The Albert and Mary Lasker Foundation bestowed two awards on five scientists for their groundbreaking research. Max D. Cooper, MD, of the Emory University School of Medicine in Atlanta, GA, and Jacques Miller, PhD, of the Walter and Eliza Hall Institute of Medical Research in Parkville, Australia, received the 2019 Albert Lasker Basic Medical Research Award for identifying the two classes of lymphocytes, B cells and T cells. H. Michael Shepard, PhD, formerly of Genentech; Dennis J. Slamon, MD, of the University of California, Los Angeles; and Axel Ullrich, PhD, of the Max Planck Institute of Biochemistry in Martinsried, Germany—shared the 2019 Lasker–DeBakey Clinical Medical Research Award for developing the first mAb, trastuzumab.
Industrial hypertension program in a rural state. Efficacy and cost effectiveness
Authors: C. C. Walworth
Journal: JAMA (1977)

A program was designed to evaluate the efficacy and cost of detecting and treating hypertension in an industrial population of a rural state. Original screening and evaluation was initiated by a trained blood-pressure technician team, but initiation of therapy was the responsibility of the private physician. Follow-up data were obtained at one year by rescreening in 83% and by telephone contact in 91% of the original hypertensive patients. Eighty-three percent of those patients with moderate or severe hypertension complied with physician visits. The condition of 60% of the treated patients was controlled, and the condition of 74% was improved. The total cost per patient treated for one year was $250; per patient with controlled hypertension, $446; and per patient with controlled or improved hypertension, $362. (<i>JAMA</i>237:1942-1945, 1977)
CERTAIN EPIDEMIC MICRO-ORGANISMS OF THE RESPIRATORY TRACT
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QUANTITATIVE BACTERIOLOGY OF THE TONSILS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Justifiable Indications Cited In Single Unit Transfusions
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brucella Nephritis
Authors: GEORGE DUNEA
Journal: Annals of Internal Medicine (1969)

Two patients with Brucella suis infection had severe renal involvement. Clinical features included transient azotemia, massive proteinuria, hypertension, and later frequency and dysuria. Renal morphological studies revealed a diffuse interstitial nephritis with focal and local glomerular lesions. In one patient clinical and pathological signs of renal disease persisted for over 3 years, suggesting that brucellosis may be a precursor of chronic renal disease.
Oncology Research Program
Journal: Journal of the National Comprehensive Cancer Network (2012)

The goal of the Highlights of the NCCN Oncology Research Program (ORP) is to provide readers with more information on the ORP, including studies currently accruing patients.For more information on specific trials, including patient selection criteria, please use the contact information listed with each study.For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, please access the NCCN ORP pages at NCCN.org/clinical_trials/ clinicians.asp. Highlights of the NCCN Oncology Research ProgramThe NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research.Since the program's establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions.Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions.All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.
Organization, Strategy and Tactics of the Army Medical Services in War
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Directions
Authors: Daisy Bassen
Journal: Annals of Internal Medicine (2019)

Ad Libitum21 May 2019DirectionsDaisy Bassen, MDDaisy Bassen, MDEast Greenwich, Rhode Island (D.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-3206 Audio Reading - “Directions” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Directions” by Daisy Bassen, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I wish my lane was bordered by hedgerows,Berries ripe, red, bright enough for birdsTo see easily, sweet and mellow, with seedsTo spit out on the turned earth. Forster's lane,Or Austen's, with dust enough to dirty my hems,To trip along with the turning of the day.In front of me, ... Author, Article, and Disclosure InformationAffiliations: East Greenwich, Rhode Island (D.B.)Current Author Address: Daisy Bassen, MD; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “Directions” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Directions” by Daisy Bassen, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 21 May 2019Volume 170, Issue 10Page: 731KeywordsAmbulancesBoneDustHemorrhageOxygenSodium ePublished: 21 May 2019 Issue Published: 21 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Epiphyseal Disorders
Authors: Frederic Shapiro
Journal: New England Journal of Medicine (1987)

THE epiphyses of developing bones are responsible for longitudinal growth and for shaping the articular surfaces. Epiphyseal disorders in children, therefore, can lead to shortness of the involved bone, to angular deformity, and to joint incongruity, which predisposes the patient to osteoarthritis. This review will concentrate on progress in understanding and treating three groups of disorders: skeletal dysplasias, fractures of the growth plate, and discrepancies in the length of the lower extremities. The epiphyseal regions will be described in histologic detail, and the relations between structure and function will be discussed briefly. Medical knowledge has moved beyond representations of gross . . .